-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Orthopoxvirus
- Others
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Virus Protease
- Antiviral intermediates
HCV-IN-38
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/hcv-in-38.gif)
| Category | Hepatitis C Virus (HCV) |
| Description | HCV-IN-38 is a potent, selective and orally active HCV inhibitor (EC50=15 nM, SI=431). HCV-IN-38 has high anti-HCV activity and low cytotoxicity. HCV-IN-38 has a good safety and oral pharmacokinetic profile. |
Product Information
| Synonyms | HCV-IN-38|HY-115989|CS-0434763 |
| Molecular Weight | 500.9 |
| Molecular Formula | C22H24ClF3N4O4 |
| Canonical SMILES | CN(C)C1CN(C1)CC2=C(C=C(C=C2)NC(=O)C3=CC(=C(C=C3)OCCCl)[N+](=O)[O-])C(F)(F)F |
| Purity | ≥98% (HPLC) |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| Complexity | 703 |
| Exact Mass | 500.1438174 |
| In Vitro | HCV-IN-38 (compound 80) (0-20 μM; 72 hours) exhibits high anti-HCV activity with EC50=15 nM and low cytotoxicity with CC50=6.47 μM in Huh7.5 cells. HCV-IN-38 (2 μM; 2 hours) has moderate permeability (0.5 < Papp < 2.5 (×10-6 cm/s)). |
| In Vivo | HCV-IN-38 (2 μM; 4 hours) has decent plasma stability (t1/2, rat=16.9 h and t1/2, human=19.9 h). HCV-IN-38 (2 mg/kg for i.p., 10 mg/kg for p.o., single) exhibits satisfying PK properties with an oral total exposure (AUC) of 1502 ng h/mL, medium in vivo clearance (38.3 mL/min/kg), Cmax of 452 ng/mL, and moderate bioavailability of 34%. HCV-IN-38 (50-200 mg/kg; i.p., single) has modest safety profiles with LD50 values higher than 150 mg/kg. |
| Target | EC50: 15 nM (HCV) in Huh7.5 cells |
| XLogP3-AA | 3.7 |
